SE8303463D0 - Nukleotidsekvens som kodar ytantigenet av hepatit b-virus, vektor innehallande nemnda nukleotidsekvens, forfarande for erhallande derav samt erhallet antigen - Google Patents

Nukleotidsekvens som kodar ytantigenet av hepatit b-virus, vektor innehallande nemnda nukleotidsekvens, forfarande for erhallande derav samt erhallet antigen

Info

Publication number
SE8303463D0
SE8303463D0 SE8303463A SE8303463A SE8303463D0 SE 8303463 D0 SE8303463 D0 SE 8303463D0 SE 8303463 A SE8303463 A SE 8303463A SE 8303463 A SE8303463 A SE 8303463A SE 8303463 D0 SE8303463 D0 SE 8303463D0
Authority
SE
Sweden
Prior art keywords
recovery
pct
antigen
virus
nucleotid sequence
Prior art date
Application number
SE8303463A
Other languages
English (en)
Other versions
SE462530B (sv
SE8303463L (sv
Inventor
F Galibert
P Tiollais
P Charnay
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR7921811A external-priority patent/FR2464269B1/fr
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Publication of SE8303463L publication Critical patent/SE8303463L/sv
Publication of SE8303463D0 publication Critical patent/SE8303463D0/sv
Publication of SE462530B publication Critical patent/SE462530B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10111—Atadenovirus, e.g. ovine adenovirus D
    • C12N2710/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/22—Viral peptide or viral protein
    • Y10S930/223—Hepatitis related

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SE8303463A 1979-08-30 1983-06-16 Immunogena peptider, som inducerar in vivo produktion av aktiva antikroppar med avseende paa hepatit b-virus SE462530B (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR7921811A FR2464269B1 (fr) 1979-08-30 1979-08-30 Sequence nucleotidique codant l'antigene de surface du virus de l'hepatite b, procede permettant son obtention et antigene obtenu
FR8009039A FR2480779B2 (fr) 1979-08-30 1980-04-22 Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur

Publications (3)

Publication Number Publication Date
SE8303463L SE8303463L (sv) 1983-06-16
SE8303463D0 true SE8303463D0 (sv) 1983-06-16
SE462530B SE462530B (sv) 1990-07-09

Family

ID=26221334

Family Applications (3)

Application Number Title Priority Date Filing Date
SE8102726D SE8102726L (sv) 1979-08-30 1981-04-29 Nukleotidsekvens som kodar ytantigenet av hepatit b-virus,vektor innehallande nemda nukleotidsekvens,forfarande for erhallande derav samt erhallet antigen
SE8102726A SE463459B (sv) 1979-08-30 1981-04-29 Vektor innehaallande dna-sekvens kodande foer ett ytantigen hos hepatit b virus
SE8303463A SE462530B (sv) 1979-08-30 1983-06-16 Immunogena peptider, som inducerar in vivo produktion av aktiva antikroppar med avseende paa hepatit b-virus

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SE8102726D SE8102726L (sv) 1979-08-30 1981-04-29 Nukleotidsekvens som kodar ytantigenet av hepatit b-virus,vektor innehallande nemda nukleotidsekvens,forfarande for erhallande derav samt erhallet antigen
SE8102726A SE463459B (sv) 1979-08-30 1981-04-29 Vektor innehaallande dna-sekvens kodande foer ett ytantigen hos hepatit b virus

Country Status (12)

Country Link
US (1) US4428941A (sv)
JP (1) JPS6362198B2 (sv)
BE (1) BE884988A (sv)
CA (1) CA1163585A (sv)
CH (1) CH663796A5 (sv)
DE (1) DE3049831C2 (sv)
FR (1) FR2480779B2 (sv)
GB (1) GB2070621B (sv)
LU (1) LU88365I2 (sv)
NL (1) NL192880C (sv)
SE (3) SE8102726L (sv)
WO (1) WO1981000577A1 (sv)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416996B1 (en) * 1978-12-18 2002-07-09 Institut Pasteur Nucleotide sequence comprising the genome of hepatitis b virus, nucleotide sequence coding the surface antigen of the hepatitis b virus, vectors containing the nucleotide sequences, process for the preparation thereof, and antigen obtained thereby
ES487106A0 (es) * 1978-12-22 1981-05-16 Biogen Nv Un metodo para producir al menos un polipeptido que muestra antigenicidad de hbv
EP0182442B2 (en) * 1978-12-22 1996-04-03 Biogen, Inc. Recombinant DNA molecules and their method of production
US6297355B1 (en) 1978-12-22 2001-10-02 Biogen, Inc. Polypeptides displaying HBV antigenicity or hbv antigen specificity
US5196194A (en) * 1979-05-24 1993-03-23 The Regents Of The University Of California Vaccines containing Hepatitis B S-protein
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
USRE34705E (en) * 1979-08-30 1994-08-23 Institut Pasteur Nucleotidic sequence coding the surface antigen of the hepatitis B virus, vector containing said nucleotidic sequence, process allowing the obtention thereof and antigen obtained thereby
EP0038765B1 (fr) * 1980-04-22 1987-09-02 Institut Pasteur Vaccin contre l'hépatite virale B, procédé et cellules eucaryotes transformées pour la production de ce vaccin
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
US4769238A (en) 1981-08-04 1988-09-06 The Regents Of The University Of California Synthesis of human virus antigens by yeast
ZW18282A1 (en) * 1981-08-31 1983-03-23 Genentech Inc Preparation of polypeptides in vertebrate cell culture
US4741901A (en) * 1981-12-03 1988-05-03 Genentech, Inc. Preparation of polypeptides in vertebrate cell culture
EP0082789B1 (en) * 1981-12-22 1987-04-08 Baylor College of Medicine Immunological composition and method for hepatitis b virus
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
JPS5931799A (ja) * 1982-08-16 1984-02-20 Science & Tech Agency Ｂ型肝炎ウイルス遺伝子を組込んだ組換えプラスミド
US4820642A (en) * 1983-04-04 1989-04-11 The Regents Of The University Of California Amplified expression vector
US4575495A (en) * 1983-05-12 1986-03-11 New York Blood Center, Inc. Synthetic antigenic peptide derived from Hepatitis B surface antigen
US4847080A (en) * 1984-03-07 1989-07-11 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers
US5324513A (en) * 1984-03-07 1994-06-28 Institut Pasteur Composition useful for the fabrication of vaccines
US4861588A (en) * 1985-02-05 1989-08-29 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US5204096A (en) * 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US4599231A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) * 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
WO1985004103A1 (en) * 1984-03-09 1985-09-26 Scripps Clinic And Research Foundation Synthetic hepatitis b virus vaccine including both t cell anc b cell determinants
SU1470739A1 (ru) * 1984-07-16 1989-04-07 Всесоюзный кардиологический научный центр АМН СССР Гексапептид, обладающий гепатопротективным действием
US4743553A (en) * 1984-07-18 1988-05-10 W. R. Grace & Co. Synthetic genes for bovine parainfluenza virus
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
JPH0745514B2 (ja) * 1985-08-20 1995-05-17 武田薬品工業株式会社 新規蛋白質およびその製造法
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
WO1987007896A1 (en) * 1986-06-20 1987-12-30 Scripps Clinic And Research Foundation T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
US4778784A (en) * 1987-01-07 1988-10-18 Baylor College Of Medicine Cyclic peptide and method of use for inducing an immunological response to hepatitis B virus
ATE207535T1 (de) * 1987-06-22 2001-11-15 Medeva Holdings Bv Hepatitis-b-oberflächenantigen enthaltendes peptid
US5162226A (en) 1987-08-24 1992-11-10 University Of Tennessee Research Corp. (U.T.R.C.) Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically engineered products
US5359100A (en) * 1987-10-15 1994-10-25 Chiron Corporation Bifunctional blocked phosphoramidites useful in making nucleic acid mutimers
DE68928124T2 (de) 1988-09-02 1997-10-16 Chiron Corp., Emeryville, Calif. Makrophagenabgeleiteter entzündungsmediator(mip-2)
CA2065287C (en) * 1989-09-15 1999-12-21 Tatsuo Miyamura New hcv isolates
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
US20010053367A1 (en) * 1991-08-26 2001-12-20 Prodigene, Inc. Vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6322789B1 (en) 1991-08-26 2001-11-27 Epimmune, Inc. HLA-restricted hepatitis B virus CTL epitopes
US5780036A (en) * 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
US5612487A (en) * 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US6607727B1 (en) 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6689363B1 (en) 1992-01-29 2004-02-10 Epimmune Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US7611713B2 (en) * 1993-03-05 2009-11-03 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide compositions
US20110097352A9 (en) * 1992-01-29 2011-04-28 Pharmexa Inc. Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions
US6235288B1 (en) * 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
WO1994020079A1 (en) 1993-03-10 1994-09-15 Smithkline Beecham Corporation Human brain phosphodiesterase
WO1997010347A1 (en) * 1995-09-15 1997-03-20 Howard John A Expression cassettes and methods for delivery of animal vaccines
US6087128A (en) 1998-02-12 2000-07-11 Ndsu Research Foundation DNA encoding an avian E. coli iss
WO2002080848A2 (en) * 2001-04-09 2002-10-17 Mayo Foundation For Medical Education And Research Methods and materials for cancer treatment
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US20040057969A1 (en) * 2002-09-20 2004-03-25 Smith Mark L Compositions containing stabilized hepatitis antigen and methods of their use
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
ZA200804078B (en) * 2005-10-13 2009-09-30 Virexx Medical Corp Chimeric hepatitis C virus antigens for eliciting an immune response
US8969033B2 (en) 2005-11-02 2015-03-03 Battelle Energy Alliance, Llc Alteration and modulation of protein activity by varying post-translational modification
JP4685674B2 (ja) * 2006-03-20 2011-05-18 株式会社東海理化電機製作所 ウエビング巻取装置
US8492114B2 (en) 2008-01-25 2013-07-23 Battelle Energy Alliance, Llc Methods of combined bioprocessing and related microorganisms, thermophilic and/or acidophilic enzymes, and nucleic acids encoding said enzymes
US9732330B2 (en) 2008-01-25 2017-08-15 Battelle Energy Alliance, Llc Methods of combined bioprocessing and related microorganisms, thermophilic and/or acidophilic enzymes, and nucleic acids encoding said enzymes
US7923234B2 (en) 2008-01-25 2011-04-12 Battelle Energy Alliance, Llc Thermal and acid tolerant beta-xylosidases, genes encoding, related organisms, and methods
US8497110B2 (en) 2008-01-31 2013-07-30 Battelle Energy Alliance, Llc Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods
US8557557B2 (en) 2008-01-31 2013-10-15 Battelle Energy Alliance, Llc Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from Alicyclobacillus acidocaldarius and related organisms, methods
MX2010008250A (es) 2008-01-31 2010-11-09 Battelle Energy Alliance Llc Genes que degradan el biopolimero termofilico y termoacidofilico y enzimas a partir de alicyclobacillus acidocaldarius, metodos y organismos relacionados.
US8426185B2 (en) 2008-01-31 2013-04-23 Battelle Energy Alliance, Llc Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from Alicyclobacillus acidocaldarius and related organisms, methods
MX2010008575A (es) 2008-02-22 2010-12-07 Battelle Energy Alliance Llc Control transcripcional en alicyclobacillus acidocaldarius y genes, proteinas y metodos asociados.
CA2712101A1 (en) 2008-02-26 2009-12-03 Battelle Energy Alliance, Llc Thermophilic and thermoacidophilic sugar transporter genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods
MX2010008249A (es) 2008-02-27 2010-11-12 Battelle Energy Alliance Llc Genes de glicosilacion termofilica y termoacidofilica y enzimas a partir de alicyclobacillus acidocaldarius y metodos, organismos relacionados.
AU2009251767A1 (en) 2008-02-28 2009-12-03 Battelle Energy Alliance, Llc Thermophilic and thermoacidophilic metabolism genes and enzymes from Alicyclobacillus acidocaldarius and related organisms
US8858952B2 (en) 2009-02-19 2014-10-14 Mayo Foundation For Medical Education And Research Methods and materials for generating T cells
EP2409155A1 (en) 2009-03-15 2012-01-25 Technion Research and Development Foundation, Ltd. Soluble hla complexes for use in disease diagnosis
US20110275135A1 (en) 2010-05-05 2011-11-10 Battelle Energy Alliance, Llc Genetic elements, proteins, and associated methods including application of additional genetic information to gram (+) thermoacidophiles
AU2013221309B2 (en) 2012-02-17 2017-03-30 Mayo Foundation For Medical Education And Research Methods and materials for generating CD8+ T cells having the ability to recognize cancer cells expressing a HER2/neu polypeptide
WO2013140393A1 (en) 2012-03-21 2013-09-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Peptides derived from the d1 - domain of nkp46
MX2022003658A (es) 2019-09-30 2022-04-25 Gilead Sciences Inc Vacunas contra el virus de la hepatitis b (vhb) y metodos para tratar el vhb.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU257278A (en) * 1977-11-08 1984-02-29 Genentech Inc Process for obtaining a recombinat clone carrier
FR2422685A1 (fr) * 1978-04-14 1979-11-09 Pasteur Institut Vecteurs, derives du bacteriophage lambda, permettant l'insertion et l'expression d'un gene, procaryote ou eucaryote, sous le controle du promoteur et de l'operateur de l'operon lactose de la bacterie escherichia coli
FR2428075A1 (fr) * 1978-06-08 1980-01-04 Pasteur Institut Procede de production de proteines par expression des genes correspondants dans des bacteries et vecteurs susceptibles d'etre mis en oeuvre dans de tels procedes
FR2444713A1 (fr) * 1978-12-18 1980-07-18 Pasteur Institut Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant
ES487106A0 (es) * 1978-12-22 1981-05-16 Biogen Nv Un metodo para producir al menos un polipeptido que muestra antigenicidad de hbv
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses

Also Published As

Publication number Publication date
US4428941A (en) 1984-01-31
SE462530B (sv) 1990-07-09
SE8303463L (sv) 1983-06-16
GB2070621B (en) 1983-05-18
SE460727B (sv) 1989-11-13
DE3049831T1 (sv) 1982-06-16
NL192880B (nl) 1997-12-01
NL192880C (nl) 1998-04-02
CA1163585A (fr) 1984-03-13
JPS6362198B2 (sv) 1988-12-01
FR2480779A2 (fr) 1981-10-23
LU88365I2 (fr) 1994-05-04
WO1981000577A1 (fr) 1981-03-05
CH663796A5 (fr) 1988-01-15
SE8102726L (sv) 1981-04-29
JPS56501128A (sv) 1981-08-13
FR2480779B2 (fr) 1986-07-18
BE884988A (fr) 1981-03-02
GB2070621A (en) 1981-09-09
NL8020315A (nl) 1981-07-01
SE463459B (sv) 1990-11-26
DE3049831C2 (de) 1992-08-27

Similar Documents

Publication Publication Date Title
SE8303463L (sv) Nukleotidsekvens som kodar ytantigenet av hepatit b-virus, vektor innehallande nemnda nukleotidsekvens, forfarande for erhallande derav samt erhallet antigen
YU46343B (sh) Dna transfer vektor, i postupak za dobijanje vakcine protiv virusa hepatitisa b
MX9700817A (es) Secuencia viral de nucleotidos de "vr-2332" y metodos de uso.
KR880011342A (ko) 비a 비b형 간염 특이 항원을 코딩하는 dna 단편, 이 dna 단편을 함유하는 발현 벡터, 형질전환체 및 이 항원의 제조방법
PT977587E (pt) Vacinas quimericas de flavivirus
NO924780L (no) Ekspresjon av spesifikke immunogener ved bruk av virusantigener
Collen et al. Heterotypic recognition of foot-and-mouth disease virus by cattle lymphocytes
Rollier et al. Maternally transferred antibodies from DNA-immunized avians protect offspring against hepadnavirus infection
EP1013757A3 (en) Attenuated forms of bovine viral diarrhea virus
NZ226904A (en) Hiv-2 env protein polypeptides and their preparation and use
ZA914682B (en) Non-a non-b sequences
NZ235474A (en) Virus capable of inducing infectious bursal disease; assay and vaccine
SE8700466D0 (sv) Vaccines against melanoma
Bopp et al. Comparative studies on novel protein antigens of streptococci of the serological group B
Vishnyakov et al. Detection of neutralizing antibodies against classical swine fever virus.
KR970010787A (ko) B형 간염 바이러스 표면항원과 c형 간염 바이러스 외피 단백질의 융합 단백질 및 이를 포함하는 혼합 백신
DK0476059T3 (da) Fremgangsmåder til forøgelse af modificeringshastigheden for metastabile bindinger
Rice Synthetic bovine parainfluenza virus.
Cao et al. Attenuated forms of bovine viral diarrhea virus
EP0949333A4 (en) MUTANT ANTIGENS OF MEASURE VIRUS AND GENES ENCODING THEM
Hodges et al. Immunodominant region of EDP 208 pili: Antigen-antibody interaction.
TH10367B (th) วัคซีนป้องกันโรคบิดสำหรับสัตว์ปีก
TH32436A (th) วัคซีนป้องกันโรคบิดสำหรับสัตว์ปีก
RU92004487A (ru) Днк, полипептид, вакцина, вектор, микроорганизм, клетка насекомого, реагент, способы лечения и профилактики, способ обнаружения антигенов
KR980000469A (ko) Hbv 항원단백질을 발현하는 키메라 폴리오바이러스 백신벡터를 이용한 면역화 방법

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8303463-7

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 8303463-7

Format of ref document f/p: F